Key result
Higher circulating very-long-chain saturated fatty acids linked to ~39% lower incident heart failure risk.
Why the study?
Elevated saturated fatty acids have been linked to higher cardiovascular risk, but the associations of long- and very-long-chain saturated fatty acids with incident heart failure remain unclear.
Are higher circulating levels of long and very-long-chain saturated fatty acids associated with a reduced risk of incident heart failure in a prospective cohort?
Cohort (n=6,408)
Yes
Are higher circulating levels of long and very-long-chain saturated fatty acids associated with a reduced risk of incident heart failure in a prospective cohort?
Hazard Ratio: 0.61 (95% CI 0.43–0.84)
Higher circulating levels of long and very-long-chain saturated fatty acids are independently associated with a reduced risk of incident heart failure, identifying them as potential biomarkers for cardiovascular risk stratification.
BACKGROUND Elevated saturated fatty acids (SFAs) have generally been associated with higher cardiovascular risk, whereas emerging evidence suggests that long- and very-long-chain SFAs (LVLSFAs) may be inversely associated with cardiometabolic outcomes. OBJECTIVE This study aimed to investigate the associations of circulating LVLSFAs with incident heart failure (HF) in a prospective US cohort. METHODS We conducted a prospective analysis of 6408 participants from the Multi-Ethnic Study of Atherosclerosis cohort (2002-2015). Plasma phospholipid fatty acids (FAs) were measured and expressed as % of total FAs. Cox proportional hazards models, adjusted for established risk factors, estimated hazard ratios (HRs) and 95% CIs for associations between LVLSFAs (as both continuous and quartile) and HF. RESULTS Over a median follow-up of 14 years, 320 cases of HF were identified. Significant inverse associations were observed between incident HF and a 1% increase in the concentration of SFAs (expressed as a percentage of total FAs) for C18:0 (0.91; 0.84-0.98), C20:0 (0.19; 0.06-0.57), and C22:0 (0.62; 0.44-0.87). Quartile analyses revealed that participants in the Q3 of C18:0 had a 30% lower risk of HF compared to the Q1 (0.70, 0.50-0.98). For C20:0 and C22:0, the strongest inverse associations were observed in the Q4 vs Q1, with HRs of 0.61 (0.43-0.84) and 0.62 (0.44-0.87), respectively. These associations were consistent across subgroups by sex, age, race, body mass index, smoking status, and hypertension, with a stronger inverse association for C18:0 among participants with diabetes (P interaction = .007). CONCLUSION These results highlight VLCSFAs as promising biomarkers for HF risk stratification and warrant further investigation into the underlying biological mechanisms.
No takes yet. Share an insight, caveat, or question.
Ramezankhani et al. (2026) conducted a cohort in Incident heart failure (n=6,408). Circulating long- and very-long-chain saturated fatty acids (LVLSFAs) vs. Lower concentrations (e.g., Quartile 1) was evaluated on Incident heart failure (HR 0.61, 95% CI 0.43-0.84). Higher circulating levels of long- and very-long-chain saturated fatty acids like C20:0 were associated with a lower risk of incident heart failure (Q4 vs Q1 HR 0.61; 95% CI 0.43-0.84).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: